Millie Das, MD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Sanofi/Genzyme
    Topic: 
    lung cancer advisory board
    Date added: 
    07/31/2023
    Relationship end date: 
    05/24/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Regeneron
    Topic: 
    lung cancer advisory board
    Date added: 
    07/31/2023
    Relationship end date: 
    12/01/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Eurofins
    Topic: 
    consulting
    Date added: 
    07/31/2023
    Relationship end date: 
    04/13/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Janssen
    Topic: 
    lung cancer advisory board
    Date added: 
    07/31/2023
    Relationship end date: 
    04/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Professional Services
    Ineligible company: 
    Astra Zeneca
    Topic: 
    lung cancer educational program
    Date added: 
    07/31/2023
    Relationship end date: 
    09/23/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Merck
    Topic: 
    KEYNOTE-867
    Date added: 
    07/31/2023
    Relationship end date: 
    12/31/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Genentech
    Topic: 
    IMForte
    Date added: 
    07/31/2023
    Relationship end date: 
    12/31/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Novartis
    Topic: 
    CANOPY-A
    Date added: 
    07/31/2023
    Relationship end date: 
    04/24/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    CellSight
    Topic: 
    Ara-G clinical trial
    Date added: 
    07/31/2023
    Relationship end date: 
    12/31/2023
Return to 2023 Precision Oncology Summit: Personalizing Treatment to Improve Patient Outcomes